|
Promega now offers high performance GloResponse™ Luciferase Reporter Cell Lines. The GloResponse™
NFAT-RE-luc2P HEK293 Cell Line and CRE-luc2P HEK293 Cell Line provide optimized luciferase reporter response which means easy, turnkey implementation. These cell lines can provide superior response dynamics of over 100 induction in as few as 4 hours with the CRE cell line. This large assay window beats other reporter systems, and makes the cells amenable for high-throughput screening.
The GloResponse™ NFAT-RE-luc2P HEK293 Cell Line and CRE-luc2P HEK293 Cell Line are designed for rapid and convenient analysis of cell signaling through the nuclear factor of activated T-cells (NFAT) pathway or cAMP response pathways via activation of a luciferase reporter gene. The CRE and NFAT pathways can be modulated by the action of G-Protein Coupled Receptors (GPCRs), an important class of proteins for drug development.
About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 1,450 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in twelve countries and 54 global distributors. Annual sales exceed $190 million.
|
